Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 3.23 Billion |
| Market Size (2027) | USD 3.29 Billion |
| Market Size (2032) | USD 3.62 Billion |
| Growth Rate (2027 - 2032) | 1.90 % |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
North America Sulfonylureas Market Analysis by Mordor Intelligence
The North America Sulfonylureas Market size is projected to expand from USD 3.23 billion in 2026 and USD 3.29 billion in 2027 to USD 3.62 billion by 2032, registering a CAGR of 1.9% between 2027 and 2032.
The COVID-19 pandemic had a favorable impact on the North America sulfonylureas market by highlighting the critical importance of effective diabetes management among patients affected by COVID-19. Individuals with diabetes were found to be more susceptible to severe disease progression, hospitalization, and adverse clinical outcomes following SARS-CoV-2 infection, prompting increased attention to glycemic control during the pandemic. This heightened focus on managing blood glucose levels reinforced the use of antidiabetic therapies, including sulfonylureas, across the region. Consequently, demand for diabetes medications remained strong throughout the pandemic period. Although healthcare systems faced temporary disruptions, the growing awareness of the relationship between diabetes control and COVID-19 outcomes supported market growth. As healthcare services normalized and diabetes management continued to remain a clinical priority, the North America sulfonylureas market maintained its growth momentum and is expected to expand further over the forecast period.
Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. In North America, till April 2022, the United States was having the highest COVID cases around 82 million, the country also registered the highest death rate. Sulfonylurea is an oral anti-diabetic drug used to treat type 2 diabetes. People with type 2 diabetes have chronically high blood sugar levels and sulfonylureas make the body free up more insulin.
The prevalence of diabetes has been rising steadily across North America, driven by factors such as sedentary lifestyles, unhealthy dietary habits, increasing obesity rates, and an aging population. The growing burden of diabetes in countries such as the United States and Canada has created a significant need for effective disease management strategies. Since diabetes is associated with various long-term complications, including cardiovascular disease, kidney impairment, neuropathy, and vision disorders, maintaining optimal blood glucose levels is essential. Consequently, patients require continuous monitoring and appropriate therapeutic interventions to achieve glycemic control, which is supporting demand for antidiabetic treatments across the region. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Market Trends and Insights
Rising diabetes prevalence
According to the International Diabetes Federation (IDF) Diabetes Atlas 2024, North America and the Caribbean continue to account for a significant share of the global diabetes burden, with millions of adults living with the disease across the region. The increasing prevalence of obesity, sedentary lifestyles, and an aging population has contributed to the growing incidence of type 2 diabetes. As diabetes requires long-term glycemic management to prevent complications such as cardiovascular disease, kidney damage, neuropathy, and vision impairment, the rising patient population is expected to drive demand for antidiabetic therapies, including sulfonylureas, during the forecast period.
According to the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, 'Patients want effective treatment options for diabetes that are as minimally intrusive on their lives as possible, and the FDA welcomes the advancement of new therapeutic options that can make it easier for patients to control their condition.' Type 2 diabetes is increasingly prevalent and associated with an increased cardiovascular and renal disease risk. Along with lifestyle changes, metformin is usually the first-line pharmacotherapy, and sulfonylureas are added after metformin failure.
Sulfonylureas are a group of medicines used to manage Type 2 diabetes. Sulfonylureas lowers blood glucose levels by stimulating insulin release from the Beta cells of the pancreas. Their action depends on the presence of functioning Beta cells. Therefore, sulfonylureas do not work in people with type 1 diabetes. Sulfonylureas are insulin secretagogues as they work by causing the body to secrete insulin. Sulfonylureas bind to a channel of proteins in the pancreas (ATP-sensitive potassium channel) that increases the amount of insulin produced by pancreatic beta cells.
Most health insurance plans cover diabetes medications because they are considered medically necessary. Medicare generally covers diabetes medications. The American Diabetes Association includes a guide to Medicare and diabetes prescription drug benefits. For patients covered by insurance, typical out-of-pocket costs consist of a prescription drug copay ranging from USD 10 to USD 50, depending on the drug. If the patient takes multiple drugs, copays can total USD 200 monthly or more.
Owing to the rising rate of obesity, growing genetic factors for type-2 diabetes, the increasing prevalence, and the factors above, the market will likely continue to grow.
The United States holds the highest market share in the North America Sulfonylureas Market in the current year
The United States holds the highest market share of about 53.6% in the North America Sulfonylureas Market in the current year.
An estimated 1.4 million Americans are diagnosed with diabetes every year, according to the American Diabetes Association. Diabetes is one of the leading causes of death in Canada and other North American countries. The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients with type 2 diabetes, currently capture more than half the sales in the anti-diabetic market. Oral anti-diabetic agents work in various ways to reduce blood sugar levels in people with type 2 diabetes. Some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals.
According to the American Diabetes Association's Standards of Medical Care in Diabetes, for lower-risk patients in whom hypoglycemia is likely not an issue, sulfonylureas are used as add-ons to metformin. In addition to using health insurance to help cover the costs of prescription drugs, many pharmaceutical companies also offer deals on the cost of prescription drugs.
Owing to the factors above, the market is expected to grow during the forecast period.
Competitive Landscape
Market Concentration
The North America Sulfonylureas market is fragmented, with major manufacturers like Pfizer, Sanofi, Mylan, Merck, etc., having a global market presence and other regional manufacturers.
North America Sulfonylureas Industry Leaders
-
Mylan
-
Lupin
-
Merck and Co.
-
Pfizer Inc.
-
Sanofi Aventis
- *Disclaimer: Major Players sorted in no particular order
North America Sulfonylureas Market Companies Covered in this Report
- Pfizer
- Sanofi
- Mylan
- Merck
- Lupin
- Alembic
Recent Industry Developments in North America Sulfonylureas Market
- March 2022: Because of the similarities in chemical structure and mode of action, the Food and Drug Administration considered the possible increased risk of cardiovascular mortality from tolbutamide applied to all other sulfonylurea drugs. Therefore, the labeling for oral hypoglycemic drugs of the sulfonylurea class shall include a warning concerning the possible increased risk of cardiovascular mortality associated with such use as 'Special Warning on Increased Risk of Cardiovascular Mortality.'
- January 2022: The 2022 ADA PPC adaptation emphasizes incorporating therapy rather than a sequential add-on, which may require adjustment of current therapies (Dipeptidyl peptidase 4 inhibitors, Glucagon-like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitors, sulfonylurea, thiazolidinedione). The therapeutic regimen should be tailored to comorbidities, patient-centered treatment factors, and management needs according to sections 10 and 11 in the complete 2022 Standards of Care for CVD and CKD risk management.
North America Sulfonylureas Market Report Scope
The sulfonylureas are a class of agents that lower blood sugar by increasing the release of insulin from the pancreas. The North America Sulfonylureas Market is segmented into geography (United States, Canada, and the rest of North America). The report offers the value (in USD million) and volume (in units million) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries provided under the Table of Contents.
Segmentation Overview
Geography
| United States |
| Canada |
| Rest of North America |
| Geography | United States |
| Canada | |
| Rest of North America |
Key Questions Answered in the Report
How big is the North America Sulfonylureas Market?
The North America Sulfonylureas Market size is expected to reach USD 3.23 billion in 2026 and grow at a CAGR of 1.9% to reach USD 3.62 billion by 2032.
What is the North America Sulfonylureas Market size in 2027?
In 2027, the North America Sulfonylureas Market size is expected to reach USD 3.29 billion.
Who are the key players in North America Sulfonylureas Market?
Mylan, Lupin, Merck and Co., Pfizer Inc. and Sanofi Aventis are the major companies operating in the North America Sulfonylureas Market.
What years does this North America Sulfonylureas Market cover, and what was the market size in 2025?
In 2025, the North America Sulfonylureas Market size was estimated at USD 3.17 billion. The report covers the North America Sulfonylureas Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the North America Sulfonylureas Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.